40+ page practical reference guide for auditing Medicare rates, spotting underpayments, and turning fee schedule data into operational decisions.
Looking up rates? Get the full 2026 Medicare Fee Schedule handbook.
Current CMS pricing and breakdown for Onc crvx mrna genxprsn 14bmk.
National Medicare Payment
$760.00
This fee schedule does not publish separate facility and non-facility rates for this code.
Effective Q3 2026
This item has a standard price nationwide. Your local rate will likely match the amount shown above.
| Quarter | National Medicare Payment | YoY % Change |
|---|---|---|
| 2026 Q3 | $760.00 | — |
| 2026 Q2 | $760.00 | — |
| 2026 Q1 | $760.00 | — |
| 2025 Q4 | — | — |
| 2025 Q3 | — | — |
| 2025 Q2 | — | — |
| 2025 Q1 | — | — |
Oncology (cervix), mrna gene expression profiling of 14 biomarkers (e6 and e7 of the highest-risk human papillomavirus [hpv] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (nasba), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker
CPT code 0463U (Oncology (cervix), mrna gene expression profiling of 14 biomarkers (e6 and e7 of the highest-risk human papillomavirus [hpv] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (nasba), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker) had a 2026 Medicare non-facility reimbursement rate of $760.00.
The 2026 National Medicare reimbursement for 0463U is $760.00. This item is paid at a standard national rate, so local variation is typically minimal.
Description: Oncology (cervix), mrna gene expression profiling of 14 biomarkers (e6 and e7 of the highest-risk human papillomavirus [hpv] types 16, 18, 31, 33, 45, 52, 58), .... Payment policies and coverage rules can still vary by setting and claim details, so confirm final guidance through CMS when needed.
| Component | Office (Non-Fac) | Facility (Hosp) |
|---|---|---|
| Work RVU | ||
| Practice Expense (PE) | ||
| Malpractice (MP) | ||
| Total RVUs | 0.00 | 0.00 |
Compare a payment against the Medicare benchmark for this code.
Medicare rates are used as a benchmark only. Actual payer contracts, modifiers, place of service, units, and billing rules may affect reimbursement. This tool is for educational and operational review purposes, not legal or billing advice.
Facility vs. non-facility pricing most commonly applies to physician services paid under the RVU-based Physician Fee Schedule. For 0463U (Clinical Laboratory Test), the payment methodology may not include both facility and non-facility rates.
Medicare reimbursement is determined by RVUs, geographic adjustments, and the annual conversion factor.
The 2026 National Average Medicare reimbursement rate for 0463U (Clinical Laboratory Test) is $760.00. This rate is effective as of January 1, 2026.
Oncology (cervix), mrna gene expression profiling of 14 biomarkers (e6 and e7 of the highest-risk human papillomavirus [hpv] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (nasba), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker
Facility vs. non-facility differences usually apply to RVU-based physician services. 0463U may not use both facility and non-facility pricing depending on its payment methodology.
Use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool on the homepage to estimate your locality-adjusted reimbursement. Medicare payment can vary based on geographic adjustments (GPCI), place of service, and claim specifics.
Coverage depends on medical necessity, setting, and Medicare policy. Some codes may be bundled, contractor-priced, or restricted. Verify final coverage guidance through CMS or your local MAC when applicable.